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Screening  to prevent disease and death is an integral  part of the modern medicine.  To ensure  that 
screening  was feasible and cost effective certain principles were  devised  , that ideally should  be 
followed in their entirety. Briefly the recommendations are that   the disease  burden has major 
health implications, has a pre-cursor lesion which is treatable and prevents progression and a 
screening system  acceptable to the population and cost effective.  Of course exceptions occur –
such as in breast cancer screening. Here the identification of a pre-cursor lesion is not the objective, 
rather detecting disease when of smaller volume and earlier stage , a principle applied to ovarian 
cancer screening.
Ovarian cancer remains a challenge to treat. In the UK there are about 7000 new cases registered 
each year, with 4-4500 deaths.  The main obstacle remains the fact that 70-75% of women at first 
presentation will have stage III /IV  disease, with 5 year survival patterns at 40% and 5% respectively. 
In stage I disease survival is at 90%  and for stage II close to 70%.  Therapeutic intervention is 
normally primary surgery followed in most cases by platinum based adjuvant chemotherapy, either 
as single agent or in combination though more recently in some advanced tumours  primary 
chemotherapy may be used with equal efficacy [1] . 
Understanding the tumour biology  is an important  pre-requisite for screening.  In ovarian cancer, 
the concept of stage I disease progressing to stage IV disease was unproven, though accepted by 
many, and for years the confusion lay in translating disease stage I-IV as a surrogate for disease 
process. Disease stage is but  the description of disease spread at surgery and does not mean that 
the progression from I-IV is inevitable.  However, such stepwise progression was assumed at that 
time of screening.  Another element is the more recently  accumulating research indicating that  the 
distal portion of the fallopian tube is the origin of  many ‘ovarian’ serous tumours. With careful 
histological examination, pre-malignant lesions  can be  identified  in tubes removed at prophylactic 
surgery, and animal models have supported the theory. This information was not available when 
trials on screening for ovarian cancer commenced. 
In ‘high risk’ populations the value of screening could be identified more rapidly compared to 
population screening. Approximately 10% of ovarian cancers have an inherited genetic component, 
the majority related to BRCA 1 and 2  mutations. The life- time risk of developing ovarian cancer is 
estimated at 50% for BRCA1 and 20-30%% for BRCA2 carriers,  compared with a lifetime risk of 
about 2% in the general population. 
There are a few randomised trials reported in the literature. Equally there are numerous other 
reports on the experiences of screening , but it is the RCTs and more structured reports which will 
form the evidence  base should screening be considered within the context of a health strategy.
The earliest report from an RCT was in 1999, where over 22,000 women were invited to be involved 
in the study, which  randomly assigned  women to either an observational  arm  or screening with 
annual CA125 and trans-vaginal scans.  [2]This pilot study reported no difference in the incidence of 
detected  cancers, but interestingly, an improved survival in the screened population.  At the same 
time, and in consideration of a possible trial, work was undertaken compiling all the available 
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literature on ovarian cancer screening, which  revealed a stage shift , with 50% of screen detected 
cases found to be at  stage I/II disease, rather than at 25% in non- screened populations. Such a 
stage shift could increase cure rates and prevent deaths and randomised studies were commenced.
The largest study called  UKCTOCS  has recruited over 200,000 women (50-74 years), half of whom 
form the control population and the remainder screened using either serum CA125 or trans-vaginal 
scans as the first screen.  The final results are expected in late 2015. The US study 
PLCO(pancreatic,lung,colonic  and ovarian cancer study)  has already reported. [3]. Over 78,000 
women were recruited and randomised to annual  serum CA125 and trans-vaginal scans, versus 
normal clinical care. The incidence of cancers in both arms were equivalent, there was no stage shift 
noted, and the cumulative ovarian cancer mortality the same.  This was the first study to challenge 
the value of screening. Another RCT by a Japanese group was published in 2008, and over 80,000 
women were recruited with similar approach to the PLOC study. Though there were more women in 
screening arm with stage I disease (64% vs 38%) this was not statistically significant and the overall 
impact regarding mortality has not yet been reported [4].
With respect to women at high risk of ovarian cancer, based on the detection of BRCA mutations or 
by family history, another study UKFOCCS, was developed [5]. In the phase I study over 3800 women 
were enrolled  and underwent annual CA125 and scans, the results indicated that to achieve a stage 
shift, screening with CA125 every 4 months was necessary and a  phase II  study followed .  Some 
patients from the phase I study was transferred to the phase II , and with further recruitment over 
4500 women were recruited. The results, presented and the ASCO meeting (2103) revealed no stage 
shift, no benefit regarding mortality and  concluded  that screening in this population was ineffective 
and prophylactic surgery afforded the best  preventative measure. Notably in the study they 
mention  the increased detection of low volume  Stage III disease  in the screened  group, but  not 
reflected in improved  overall survival -the studies objective
Thus the present position looks  somewhat bleak, though accepting that the largest study has yet to 
report .  Knowing now that the fallopian tube is the primary source of many ovarian cancers  and 
accepting  that there are 2 distinct entities low and high grade ovarian cancer, with different 
carcinogenic pathways, then focusing on the ovary as the organ to screen may have been erroneous.  
Again, the retrospectoscope remains the most accurate instrument we have.  Should the UKCTOCS 
report a negative outcome, then other screening strategies will need to be considered and 
developed.
Page 4 of 5
Ac
ce
pte
d M
an
us
cri
ptReferences
1. Kehoe S, Hook J, Nankivell M et al. Primary chemotherapy versus primary surgery for newly 
diagnosed advanced ovarian cancer (CHORUS): an open-label, randomised, controlled, non-
inferiority trial.  Lancet  online 20th May 2015, DOI: http://dx.doi.org/10.1016/S0140-6736(14)62223-6
2. Jacobs IJ, Skates SJ, MacDonald N et al. Screening for ovarian cancer: a pilot randomised 
controlled trial. Lancet. 1999 Apr 10;353(9160):1207-10.
3. Buys SS, Partridge E, Black A et al. Effect of screening on ovarian cancer mortality: the Prostate, 
Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA. 2011 Jun 
8;305(22):2295-303. doi: 10.1001/jama.2011.766.
4. Kobayashi H, Yamada Y, Sado T et al. A randomized study of screening for ovarian cancer: a 
multicenter study in Japan. Int J Gynecol Cancer. 2008 May-Jun;18(3):414-20
5. Rosenthal AM, Fraser L, Philpott S et al. Final results of 4-monthly screening in the UK Familial 
Ovarian Cancer Screening Study (UKFOCSS Phase 2). J Clin Oncol 31, 2013 (suppl; abstr 5507)
Conflicts of Interest: none
CO AUTHORS
N/A
Sean Kehoe
CONFLICT OF INTERESTS – None to declare
Sean Kehoe
Page 5 of 5
Ac
ce
pte
d M
an
us
cri
pt
FUNDINGS
Nil applicable
Sean Kehoe
